OneVentures Welcome Image

Investment with Purpose



OneVentures builds great businesses working alongside driven and ambitious management teams, contributing venture capital and strong operational and executional team skills. The companies and the individuals we back are commercialising products and services that tackle large global market needs and seeking to accelerate their international growth and development.

OneVentures invests Australia wide and is based in Sydney with offices in Melbourne and Brisbane. Our companies operate in global markets with offices in San Francisco, Palo Alto, New Jersey, Boston, Los Angeles, Manilla, Ho Chi Minh City and London.

The firm has $320M in funds under management across 3 funds and 8 co-investment funds. Fund II and III are open for applications from technology and healthcare businesses.

A global growth investment focus drives investment selection and fund creation. OneVentures portfolio includes companies with truly disruptive and innovative products tackling multi-$Billion problems from healthcare: needle free vaccine delivery, dementia patient care and allergy treatment; though to the connected world: HR management in the cloud, personalised learning and virtual communications.



Proudly supporting

Heads Over Heels

Investor Portal Log In

Connect With Us

About OneVentures

Established as an early stage investment business in 2007, the firm moved into venture capital in late 2008 and launched the only VC fund in Australia in 2010 post the global financial crisis.

The team has a stellar track record in building high growth companies in international markets. A unique blend of entrepreneurs, technology business founders and business executives combined with software, applied sciences and medical domain depth.  We apply this expertise to mentor and collaborate with Founders, CEOs and company management and provide  leadership on the boards of our investee companies. 

Our investors work with us to support our companies by providing strategic advice and access to networks. They trust us to deliver results and provide a high level of accountability and transparency.  We have an extensive investor network of high net worth investors and family offices representing approximately $20B in net worth. Exit value created for investors delivered by members of the investment team is approximately $1.5B including 4 Nasdaq companies.

We focus on bringing innovative products to global markets and hold ourselves and our companies to high standards of performance. We ensure our companies are adequately capitalised to allow management to achieve significant commercial milestones and ultimately deliver financial returns to the business owners and our investors.

We partner with some of the largest and best known global investors and corporations.



OneVentures Management Pty Ltd is a designate under OneVentures Nominees Pty Ltd's AFSL (Licence No: 462825) issued by the Australian Securities and Investments Commissions, authorising the Manager to provide such financial services as the Manager provides during the course of its duties as manager of the Fund.

The OneVentures Team

All Partners have many years of C-level, board and investment experience. Coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. The OneVentures Investment team has 7 technology related higher degrees.

Dr Michelle Deaker

Dr Michelle Deaker
Managing Partner

Dr Paul Kelly

Dr Paul Kelly
Managing Partner 

Anne-Marie Birkill

Anne-Marie Birkill
Managing Partner 

Graeme Wald

Graeme Wald

Dr Amir Zalcenstein

Dr Amir Zalcenstein
Investment Manager, Healthcare

James McGrath

James McGrath
Investment Analyst

Helen Liu

Helen Liu
Chief Financial Officer

Jelly Jakob

Jelly Jakob

Jen Ball

Jen Ball
Office Manager

Board of Directors

Walter Lewin

Walter Lewin
OneVentures Board of Directors

Simon Moore

Simon Moore
OneVentures Board of Directors

Roger Massy-Greene

Roger Massy-Greene
OneVentures Board of Directors


OneVentures has three funds, two of which are actively investing. The OneVentures Innovation and Growth Fund II and OneVentures Healthcare Fund III, have approximately $200M in available capital and are currently seeking investment opportunities in technology and healthcare businesses.

All three of our main funds are Early Stage Venture Capital Limited Partnerships (ESVCLPs) providing investors tax benefits for their VC asset class investing. We also raise additional capital alongside our funds from our limited partners as our investments mature, providing companies with the potential for larger rounds of financing and co-investment opportunities. This allow investors to improve their returns and back their favoured companies further. Recent larger raises have included rounds of up to $30M.

OneVentures is currently looking for truly transformative companies to join its portfolio of innovative companies. If you think your company has what it takes, read the Application for Funding page and submit your application now.


OneVentures Healthcare Fund III

OneVentures recently launched its $170M Healthcare Fund III, which is focused on investing in companies with products that have reached clinical proof of concept, with at least Phase 1 or equivalent trial results; a clear commercial, regulatory and reimbursement pathway; and well defined value inflection and exit points on deal entry. The OneVentures' team has deep experience in driving opportunities through the FDA regulatory process and commercialising biomedical innovations in global markets. 

The fund launched in December 2016 and is licenced under the Commonwealth government’s Biomedical Translation Fund (BTF) programme. The BTF programme was established to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential managed by leading Australian venture firms. OneVentures was granted an $85 million license supported by matching capital from its private investor network. The government funding provides benefits to investors both during the investment phase and on realisation.

The fund will invest $10 to $20 million in Australian domiciled companies commercialising medical devices, drugs in clinical development or diagnostics.

Innovation and Growth Fund Fund II

The OneVentures Innovation and Growth Fund II was launched in October 2014 with $100M in available funds for technology and healthcare businesses. 

The fund is focused on later stage companies seeking growth and development capital for offshore expansion and market growth. Fund II is screening currently for technology companies with a strong product market fit and a clear path to revenue of $3 to 5M over the next 12 months. In particular, we are looking at investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success. The fund looks to invest on average $3 to 5M into any one company although rounds of up to $10M+ are also possible.

OneVentures Innovation Fund (Fund I)

The OneVentures Innovation Fund is a $40M venture capital fund established to provide capital and expertise into early stage (seed and Series A companies). This fund was launched in 2010 with the Commonwealth Government committing $20M from its Innovation Investment Fund programme. Capital from this fund is fully deployed.

Investment Portfolio

OneVentures Innovation Fund (Fund I)

OneVentures Innovation and Growth Fund (Fund II)

Other Investments

Latest News

  • Australia’s ProTA accelerates the development of immunotherapy to treat peanut allergy

    by OneVentures Administrator | Apr 07, 2017

    Melbourne, Australia:  Allergy immunotherapy company ProTA Therapeutics Pty Ltd (ProTA) will accelerate the development of a possible treatment for life-threatening peanut allergy with the appointment of its new CEO. 


    ProTA has appointed former Mesoblast Vice President Operations Dr. Suzanne Lipe, as the company’s founding Chief Executive Officer.  Dr Lipe will drive the development of the treatment to ultimately achieve global commercialisation.

    The company estimates the market for life-saving treatments for food allergies is in excess of USD 1 billion in the United States alone.

    ProTA has licensed the promising treatment developed at Melbourne’s Murdoch Children’s Research Institute by Prof. Mimi Tang.  The treatment has been found in a clinical trial to induce tolerance to peanut in more than 80 per cent of children treated, allowing them to include peanuts as part of their regular diet.

    The treatment combines a probiotic with the gradual introduction of peanut protein, which could potentially provide a long-term cure for all food allergy sufferers, including adults.

    OneVentures led the initial $15M Series A financing for ProTA in 2016.   Further funding will come from OneVentures AUD170M Healthcare Fund III, which is dedicated solely to investing in Life Science companies in Australia.  This fund was established as part of the Federal Government’s Biomedical Translation Fund initiative and was awarded AUD85M from the Federal Government, which was matched by OneVentures investors.

    Principal of OneVentures and Chairman of ProTA Dr. Graeme Wald said, “The growing problem of food allergies presents ProTA with a multi-billion dollar opportunity, not only in peanut allergies but in several other foods. There is therefore a pipeline of products for the company to develop, which should enhance the company’s value. This is an exciting time for ProTA, as we move forward on developing life-saving treatments for food allergies.”

    OneVentures Managing Partner, Dr. Paul Kelly, said, “The appointment of Dr. Lipe will provide crucial drug development experience to ProTA as we progress our products through clinical development and to achieve commercialisation outcomes.”

    Dr Suzanne Lipe said, “I am excited to join ProTA and work closely with founder, Professor Mimi Tang, to develop life-saving treatments aimed at switching off the potential deadly allergic reaction to peanuts, that could lead to a cure for peanut allergy.” 

    Dr. Lipe has over 20 years of experience in the biotechnology and pharmaceutical industry where she has held executive management positions providing strategic direction and operational management for drug development and commercial programs, including clinical trials management, regulatory and drug approvals, manufacturing, sales and marketing, licensing and commercialization of research through partnering.

    Prior to joining ProTA, Dr. Lipe held a number of key positions at Mesoblast Limited.  She joined Mesoblast in 2008 as Vice President of Operations, managing the transition from an early stage preclinical company to filing the first IND and CTN applications for clinical trials for the company’s mesenchymal stem cell products (MPCs).  

    Dr. Lipe holds a Bachelor of Science with Honours (Pharmacology), Ph.D (Medicine) and an LL.B. from the University of Melbourne.

    About OneVentures

    OneVentures is an Australian venture capital firm with $320M under management launching its first fund in 2010. OneVentures utilises its strengths in business building to accelerate portfolio company performance. OneVentures has delivered exit value to investors of $1.5B including 4 Nasdaq companies. A global growth focus drives investment selection with portfolio companies addressing multi-billion dollar problems from breakthroughs in healthcare (e.g. needle free vaccine delivery) through to the transformation of online education (e.g. next generation courseware and personalised learning) and the connected world (IoT, SaaS and virtual reality).

    Read more about OneVentures at

    About ProTA Therapeutics Pty Ltd

    ProTA Therapeutics is a private company established in late 2016 to develop and commercialise treatments for food allergy. The technology is based upon years of research by Prof. Mimi Tang of the Murdoch Children’s Research Institute in Melbourne.

    Media enquiries

    Dr Suzanne Lipe

    Rashmi Punjabi, Honner

    0466 658 475 


Full story

Contact Us

For Entrepreneurs

We are now screening companies for OneVentures Fund II which is a Series A and beyond growth fund focusing on the technology sector. To qualify for funding, your company should meet the following criteria:

  • Australian domiciled company
  • We invest in technology companies from many sectors, but we are particularly interested in companies from the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security
  • If a life sciences company, your product should have a strong proof of concept and be at a minimum, in a late stage clinical trial and/or well progressed through the regulatory process
  • If from another sector, your company should be generating sustainable revenue and have a strong market validation
  • Approaching profitability with capital required to fuel growth and global expansion

If you meet the above criteria, send us a brief document (a 2-page executive summary or introductory PowerPoint is sufficient, please do not send larger documents or full information memorandums at this stage) covering at a minimum the following points to

  • Summarize in 2 sentences what your company does (this is important)
  • Identify the market, value proposition and your competitive advantage
  • Tell us about your progress to date
  • State your revenue for the last financial year and projected revenue for current financial year
  • Indicate capital required and how it will be used
  • Include 3 point bios of each executive and contact details

We will review your proposal and endeavour to revert to you within 2 weeks. 


For Investors

Investor enquiries:


General Enquiries

General enquiries:
Telephone: +61 2 8205 7379


OneVentures Pty Ltd
Level 13
179 Elizabeth Street
Sydney NSW 2000


The Precinct
Level 2, 315 Brunswick St
Fortitude Valley QLD 4006



C/o FB Rice
Level 14, 90 Collins Street
Melbourne VIC 3000